Stemline Therapeutics (STML) Shares Down 10.3% After Earnings Miss

Stemline Therapeutics Inc (NASDAQ:STML) fell 10.3% during trading on Monday following a dissappointing earnings announcement. The company traded as low as $14.29 and last traded at $14.44. 853,496 shares traded hands during mid-day trading, an increase of 24% from the average session volume of 689,186 shares. The stock had previously closed at $16.10.

The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million for the quarter, compared to analyst estimates of $2.61 million.

Several brokerages have recently weighed in on STML. Wedbush downgraded shares of Stemline Therapeutics from an “outperform” rating to a “neutral” rating and set a $18.00 price objective for the company. in a research report on Monday. They noted that the move was a valuation call. Roth Capital set a $33.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Friday, May 10th. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. ValuEngine upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, April 4th. Finally, Piper Jaffray Companies set a $23.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 18th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $25.20.



In related news, CEO Ivan Bergstein sold 34,132 shares of the company’s stock in a transaction on Thursday, February 14th. The shares were sold at an average price of $10.98, for a total value of $374,769.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Kenneth Hoberman sold 10,557 shares of the company’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $12.05, for a total transaction of $127,211.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 180,999 shares of company stock valued at $2,048,415. 14.80% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in STML. BlackRock Inc. increased its stake in Stemline Therapeutics by 6.3% in the third quarter. BlackRock Inc. now owns 1,969,492 shares of the biopharmaceutical company’s stock valued at $32,694,000 after acquiring an additional 116,672 shares during the last quarter. MetLife Investment Advisors LLC increased its stake in Stemline Therapeutics by 54.6% in the third quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock valued at $307,000 after acquiring an additional 6,527 shares during the last quarter. Vanguard Group Inc. increased its stake in Stemline Therapeutics by 1.5% in the third quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after acquiring an additional 18,487 shares during the last quarter. Vanguard Group Inc increased its stake in Stemline Therapeutics by 1.5% in the third quarter. Vanguard Group Inc now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after acquiring an additional 18,487 shares during the last quarter. Finally, Hikari Power Ltd bought a new position in Stemline Therapeutics in the fourth quarter valued at $144,000. Hedge funds and other institutional investors own 47.73% of the company’s stock.

The company has a market cap of $701.32 million, a P/E ratio of -4.78 and a beta of 1.20.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2019/05/15/stemline-therapeutics-stml-shares-down-10-3-after-earnings-miss.html.

About Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

See Also: What is Green Investing?

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.